EZH2: biology, disease, and structure-based drug discovery

Area of Science:

• Biochemistry
• Molecular Biology
• Epigenetics

Background:

• EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), is a histone methyltransferase.
• Overexpression of EZH2 is implicated in various cancers, including prostate and breast cancer.
• EZH2 plays a role in transcriptional repression and gene activation.

Purpose of the Study:

• To review the oncogenic role of EZH2.
• To discuss the PRC2-dependent and independent functions of EZH2.
• To summarize the development of EZH2 inhibitors as potential cancer therapies.

Main Methods:

• Literature review of EZH2 functions in cancer.
• Analysis of PRC2 complex architecture and subunit roles.
• Summary of current EZH2 inhibitor development.

Main Results:

• EZH2 contributes to cancer through both PRC2-dependent and independent mechanisms.
• EZH2 interacts with other silencing enzymes like DNA methyltransferase and histone deacetylase.
• The structure and function of PRC2 subunits are critical for EZH2 activity.

Conclusions:

• EZH2 is a significant driver of oncogenesis.
• Understanding EZH2's multifaceted roles is key to developing targeted therapies.
• EZH2 inhibitors represent a promising avenue for epigenetic cancer therapy.